Andrew Pardoll
Johns Hopkins University
H-index: 168
North America-United States
Top articles of Andrew Pardoll
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade | Journal of translational medicine | Shuming Chen Tracee L McMiller Abha Soni Farah Succaria John-William Sidhom | 2024/3/5 |
CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy | OncoImmunology | Ayush Pant Brandon Hwa-Lin Bergsneider Siddhartha Srivastava Timothy Kim Aanchal Jain | 2024/12/31 |
Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Otolaryngology–Head and Neck Surgery | Hosam H Alkhatib Christopher A Maroun Meytal Guller Dylan J Cooper Evan S Wu | 2024/3 |
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy | Oncoimmunology | Ying Zheng Andriana Lebid Liam Chung Juan Fu Xiaoxu Wang | 2024/12/31 |
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma | Cell Reports Medicine | Thomas Pulliam Saumya Jani Lichen Jing Heeju Ryu Ana Jojic | 2024/2/20 |
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers | Nature | Tushar D Nichakawade Jiaxin Ge Brian J Mog Bum Seok Lee Alexander H Pearlman | 2024/4 |
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity | bioRxiv | Hong Yu Hiroshi Nishio Joseph Barbi Marisa Mitchell-Flack Paolo DA Vignali | 2024 |
Modulation of MAITs by the tumor microbiome in anti-PD1 treated cancers | Cancer Research | Pakhi Birla Lansaol Yang Cynthia Sears Fyza Shaikh Drew Pardoll | 2024/3/22 |
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses | Nature medicine | Ronan J Kelly Blair V Landon Ali H Zaidi Dipika Singh Jenna V Canzoniero | 2024/3/19 |
1481 Clinicopathological and molecular features of rhabdomyosarcoma influence their immune landscape | Alexandre Maalouf Aditya Suru Lindy Zhang Ada Tam Thet HK Aye | 2023/11/1 | |
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Journal of Clinical Oncology | Suzanne L Topalian Mario Sznol David F McDermott Harriet M Kluger Richard D Carvajal | 2023/2/10 |
Age‐associated Senescent–T Cell Signaling Promotes Type 3 Immunity that Inhibits the Biomaterial Regenerative Response | Advanced Materials | Jin Han Christopher Cherry Joscelyn C Mejias Kavita Krishnan Anna Ruta | 2023/12/12 |
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial | Nature medicine | Eugene Shenderov Angelo M De Marzo Tamara L Lotan Hao Wang Sin Chan | 2023/4 |
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen | Nature communications | Katharine M Wright Sarah R DiNapoli Michelle S Miller P Aitana Azurmendi Xiaowei Zhao | 2023/8/21 |
Abstract A079: Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages to drive tumor immunity in urologic cancers | Cancer Research | Monali Praharaj Fan Shen Alex J Lee Liang Zhao Thomas R Nirschl | 2023/6/2 |
1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients | Pakhi Birla Lansaol Yang Alex Lee Boyang Zhang Kellie N Smith | 2023/11/1 | |
Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance | Cancer Research | Sergey Nemzer Niv Sabath Assaf Wool Zoya Altber Hirofumi Ando | 2023/4/4 |
Radiation therapy and myeloid-derived suppressor cells: breaking down their cancerous partnership | Kyra M Boorsma Bergerud Matthew Berkseth Drew M Pardoll Sudipto Ganguly Lawrence R Kleinberg | 2023/11/30 | |
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology | Julie R Brahmer Charles G Drake Ira Wollner John D Powderly Joel Picus | 2023/2/1 |
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS | Gastroenterology | Kristi Briggs Ada Tam Franck Housseau Joanna Melia Drew Pardoll | 2023/4/1 |
Co-Authors
